CQDM

What CQDM does

CQDM is a Quebec-based research funding consortium founded in 2008 and headquartered in Montreal, Canada. The organization functions as a bridge between academic researchers, biotechnology startups, and the pharmaceutical industry, channeling government and industry capital into early-stage drug discovery projects. Rather than developing commercial products, CQDM deploys grants and co-investment capital through multi-party collaborations targeting high-unmet-need therapeutic areas including neuroscience (anorexia nervosa, compulsive disorders, insomnia, neuropathic pain) and gene editing tools.

The consortium operates through partnerships with major academic and industry players including McGill University, Douglas Hospital Research Centre, Brain Canada, Merck (via the Merck Digital Sciences Studio accelerator), and Will Therapeutics. Notable funding activities include a CAD $3.5 million three-year collaboration with Will Therapeutics (2026), a $100,000 USD per-startup commitment within the Merck Digital Sciences Studio cohort of 12 biopharma startups (2026), participation in DropGenie's Seed+ financing round (2026), and grants exceeding $1.6 million supporting McGill-led insomnia and neuropathic pain research (2024).

CQDM's business model is that of a publicly-funded intermediary rather than a revenue-generating enterprise. It is backed primarily by the Government of Québec and aligns with national biotech initiatives such as Brain Canada. The organization is led by CEO Diane Gosselin and Director of Business Development Jesse Paterson, with a headcount of 11–50 employees. Its revenue mechanics consist of grant inflows from provincial government and industry sponsors, which it then deploys to academic and biotech recipients through research collaborations, accelerator participation, and selective equity co-investments.

Name

CQDM

Legal name

CQDM

Website

http://www.cqdm.org

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

CQDM is a Quebec-based research funding consortium that channels government and industry capital into early-stage drug discovery, connecting academic researchers, biotech startups, and pharmaceutical partners across neuroscience and gene editing.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Research Funding

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Professional Organizations (81392)

SIC

Miscellaneous Business Credit Institution (6159)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Joint Venture CVC / Consortium Funds (Multi-corporate) (FSANAHAE), Captive CVC Fund (Dedicated corporate fund structure) (FSANAHAB)

Keywords

• Drug discovery funding
• Biopharmaceutical research
• Research consortium
• Biotech accelerator
• Academic industry collaboration

Headquarters

HQ city

Montreal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Core offering

CQDM is a Quebec-based research funding consortium that finances and coordinates drug discovery collaborations between academic researchers, biotechnology startups, and the pharmaceutical industry. It deploys government-backed grants and participates in startup accelerator programs to accelerate translational research in areas such as neuroscience, gene editing, and digital health.

Product overview

CQDM is a research consortium organization based in Quebec, Canada that funds and supports life sciences research collaborations between academia and industry. The organization does not appear to offer commercial products or services in the traditional sense; rather, it facilitates drug discovery research through funding mechanisms, startup accelerator participation, and industry-academia partnerships. Based on the source material, CQDM's activities include supporting biotechnology startups, funding research collaborations targeting neurological disorders and insomnia, and contributing to accelerator programs for biopharmaceutical innovation.

Differentiator

Problem solved

Functional benefit

Products and services

• Merck Digital Sciences Studio Accelerator Participation
• Will Therapeutics Research Collaboration Grant
• McGill University Neurological Disorder Research Grants

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core, minor and major.

• Will TherapeuticscoreStrategic or Co-development Partner · 30 June 2026CAD $3.5 million, three-year research collaboration to develop brain-penetrant small molecules targeting anorexia nervosa and other compulsive disorders. CQDM provides funding backed by Government of Québec, while Will Therapeutics and Douglas Hospital Research Centre conduct research.
• Douglas Hospital Research CentrecoreStrategic or Co-development Partner · 30 June 2026Research partner leading the Will Therapeutics collaboration for developing targeted pharmacological treatments for anorexia nervosa and compulsive disorders, with research led by Dr. Salah El Mestikawy.
• DropGeniecoreStrategic or Co-development Partner · 22 June 2026CQDM participated in DropGenie's Seed+ financing round alongside Merck Global Health Innovation Fund, Skeleton Key, Real Ventures, and Anges Québec to support commercialization of miniaturized gene editing workflows.
• MerckcoreStrategic or Co-development Partner · 13 March 2026Operates Merck Digital Sciences Studio (MDSS) accelerator in Montreal, with CQDM as funding consortium partner contributing to $100,000 USD per selected startup across 12 biopharma startups.
• CentechminorImplementation/ SI/ Consulting Partner · 13 March 2026Operating partner for Merck Digital Sciences Studio accelerator, providing mentorship and operational support to selected startups.
• McGill UniversitycoreStrategic or Co-development Partner · 3 July 2024Lead academic partner in drug discovery consortium developing novel treatments for insomnia and neuropathic pain, with research originating from the university being engineered for oral administration and human trials.
• Brain CanadamajorStrategic or Co-development Partner · 3 July 2024National partner in consortium supporting drug discovery collaboration with McGill University and industry for neurological disorder treatments.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Brain Canada: National Canadian charity funding brain research through grants and partnerships. Comparable to CQDM as a Canadian non-profit R&D funder partnering with academic institutions and government for translational health research.
• Genome Canada: Canadian federal funding agency for genomics and translational research. Highly comparable to CQDM in its consortium model, government backing, and focus on bridging academic genomics research with industry commercialization.
• adMare BioInnovations: Canadian biotech accelerator and venture builder transforming academic research into companies. Directly comparable as a Canadian organization funding and operationalizing life sciences commercialization from academia.
• Genome Québec: Quebec-based genomics research funder supporting academic-industry partnerships. Most geographically and operationally analogous to CQDM, both being Quebec-anchored biomedical research consortia with government support.
• Ontario Bioscience Innovation Organization (OBIO): Ontario health science industry consortium supporting early-stage companies. Comparable to CQDM as a Canadian regional life sciences consortium bridging research, industry, and capital, though focused more on medtech and digital health.
• Mitacs: Canadian not-for-profit funding research internships and industry-academic collaborations. Comparable to CQDM in its federally and provincially backed model that channels academic talent into commercializable research.
• Bioenterprise Canada: Canada's national agri-food and biotech accelerator with consortium-style funding. Comparable to CQDM as a Canadian accelerator that supports commercialization of life sciences R&D through partnerships and grants.

Broad incumbents

• Creative Destruction Lab: Canada-based seed-stage accelerator for science and technology ventures. Comparable to CQDM in its role within the Canadian startup ecosystem but broader in sector coverage and more oriented toward traditional venture-style acceleration.
• MaRS Discovery District: Toronto-based innovation hub supporting Canadian science and technology ventures. Comparable to CQDM as a major Canadian R&D commercialization hub but broader and located outside Quebec.
• Bill & Melinda Gates Foundation (Global Health): Large philanthropic global health research funder supporting product development partnerships. Comparable to CQDM as a health research grantmaker funding translational science, though at vastly greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/cqdm_canada
• LinkedInlinkedin.com/company/cqdm

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CQDM